OligoImmune is a new biotech led by renowned founders from MD Anderson Cancer Center (MDACC) and experienced industry leaders. Together, we are spearheading groundbreaking innovations to revolutionize cancer immunotherapy and treat fibrosis. By unlocking macrophages' incredible untapped power to combat tumors, and address fibrotic diseases, OligoImmune's approach promises to transform the way we treat cancer and fibrosis. Our technology will unleash the full potential of the body's innate immune defenses against cancer and fibrosis. Our oncology program focuses on empowering macrophages to unleash their full antitumor potential, filling a significant gap in immunotherapy options for cancer patients. In parallel, our fibrosis program focuses on reprogramming macrophages to resolve fibrosis across multiple organs, providing hope for patients with these debilitating diseases. With our revolutionary science, we have the potential to dramatically improve outcomes for patients with cancer or organ fibrosis.